Additional findings link KMT2D deletion in prostate cancer cells to increased sensitivity to both conventional chemotherapy and PARP inhibitors, making KMT2D expression status a potential novel biomarker for the prognosis of the treatment response [69]. This evidence concerns the gene KMT2D and Familial prostate cancer.